(S)-4-(4-(2-(tert-butoxycarbonylamino)propanoyloxy)but-2-ynyloxy)-3-(phenylsulfonyl)-1,2,5-oxadiazol-2-oxide | 1103594-29-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-4-(4-(2-(tert-butoxycarbonylamino)propanoyloxy)but-2-ynyloxy)-3-(phenylsulfonyl)-1,2,5-oxadiazol-2-oxide
• CAS: 1103594-29-1
• 化学式: C₂₀H₂₃N₃O₉S
• 分子量: 481.483
• InChiKey: VAFWEIBSKVOROE-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.98
• 重原子数：
  33.0
• 可旋转键数：
  7.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  160.97
• 氢给体数：
  1.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  (S)-4-(4-(2-(tert-butoxycarbonylamino)propanoyloxy)but-2-ynyloxy)-3-(phenylsulfonyl)-1,2,5-oxadiazol-2-oxide 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  Synthesis of CDDO–Amino Acid–Nitric Oxide Donor Trihybrids as Potential Antitumor Agents against Both Drug-Sensitive and Drug-Resistant Colon Cancer

  摘要：

  Seventeen CDDO-amino acid-NO donor trihybrids (4a-q) were designed and synthesized. Biological evaluation indicated that the most active compound 4c produced high levels of NO and inhibited the proliferation of drug-sensitive (HCT-8, IC50 = 0.294 mu M) and drug-resistant (HCT-8/5-FU, IC50 = 0.232 mu M) colon cancer cells, which were attenuated by an NO scavenger or typical substrate of PepT1. Furthermore, 4c triggered HCT-8 and HCT-8/5-FU cell apoptosis more strongly than CDDO-Me, inhibited the HIF-1a, Stat3, AKT, and ERK signaling, and induced the nitration of P-gp, MRP1, and BCRP proteins in HCT-8/5-FU cells. Finally, 4c had 4.36-5.53-fold less inhibitory activity against nontumor colon epithelial-like cells (CCD841, IC50 = 1.282 mu M) in vitro and inhibited the growth of implanted human drug-resistant colon cancers in mice more potently than CDDO-Me. Together, 4c is a novel trihybrid with potent antitumor activity and may be a promising candidate for the treatment of drug-resistant colon cancer.

  DOI：

  10.1021/jm5019302
• 作为产物：
  描述：

  呋咱氮氧化物供体 在 4-二甲氨基吡啶 、 sodium hydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.25h， 生成 (S)-4-(4-(2-(tert-butoxycarbonylamino)propanoyloxy)but-2-ynyloxy)-3-(phenylsulfonyl)-1,2,5-oxadiazol-2-oxide
  参考文献：
  名称：

  Synthesis of CDDO–Amino Acid–Nitric Oxide Donor Trihybrids as Potential Antitumor Agents against Both Drug-Sensitive and Drug-Resistant Colon Cancer

  摘要：

  Seventeen CDDO-amino acid-NO donor trihybrids (4a-q) were designed and synthesized. Biological evaluation indicated that the most active compound 4c produced high levels of NO and inhibited the proliferation of drug-sensitive (HCT-8, IC50 = 0.294 mu M) and drug-resistant (HCT-8/5-FU, IC50 = 0.232 mu M) colon cancer cells, which were attenuated by an NO scavenger or typical substrate of PepT1. Furthermore, 4c triggered HCT-8 and HCT-8/5-FU cell apoptosis more strongly than CDDO-Me, inhibited the HIF-1a, Stat3, AKT, and ERK signaling, and induced the nitration of P-gp, MRP1, and BCRP proteins in HCT-8/5-FU cells. Finally, 4c had 4.36-5.53-fold less inhibitory activity against nontumor colon epithelial-like cells (CCD841, IC50 = 1.282 mu M) in vitro and inhibited the growth of implanted human drug-resistant colon cancers in mice more potently than CDDO-Me. Together, 4c is a novel trihybrid with potent antitumor activity and may be a promising candidate for the treatment of drug-resistant colon cancer.

  DOI：

  10.1021/jm5019302

文献信息

• Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents
  作者：Yong Ling、Xiaolei Ye、Hui Ji、Yihua Zhang、Yisheng Lai、Sixun Peng、Jide Tian

  DOI：10.1016/j.bmc.2010.03.077

  日期：2010.5

  (NO)-releasing derivatives (11a–p) of farnesylthiosalicylic acid (FTA) were synthesized. Compounds 11d, 11f, 11k, and 11m–o displayed anti-tumor activities superior to FTA and sorafenib in most cancer cells tested. Analysis of six compounds revealed that 11d, 11f, 11n, 11o, and 11p, but not 11a that had low anti-tumor activity, produced high levels of NO, associated with their strong anti-tumor activity

  合成了法呢基硫代水杨酸（FTA）的新型基于呋喃烷的一氧化氮（NO）释放衍生物（11a – p）。在大多数测试的癌细胞中，化合物11d，11f，11k和11m - o表现出优于FTA和索拉非尼的抗肿瘤活性。对六种化合物的分析显示，具有低抗肿瘤活性的11d，11f，11n，11o和11p而不是11a产生高水平的NO，这与它们的强抗肿瘤活性有关。此外，11f的抗肿瘤活性呋喃喃部分模拟了部分被氧化，但被血红蛋白预处理减少了。重要的是，用11f治疗可抑制癌细胞中与Ras相关的信号传导。显然，11f的高抗肿瘤活性归因于癌细胞中高水平的NO产生和Ras相关信号的抑制的协同作用。我们的发现表明，呋喃喃/ FTA杂种作为治疗人类癌症的治疗剂可能具有更大的前景。